WO2001025399A3 - Non-invasive tumor imaging by tumor-targeted bacteria - Google Patents

Non-invasive tumor imaging by tumor-targeted bacteria Download PDF

Info

Publication number
WO2001025399A3
WO2001025399A3 PCT/US2000/027397 US0027397W WO0125399A3 WO 2001025399 A3 WO2001025399 A3 WO 2001025399A3 US 0027397 W US0027397 W US 0027397W WO 0125399 A3 WO0125399 A3 WO 0125399A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumor
marker gene
detecting
gene product
methods
Prior art date
Application number
PCT/US2000/027397
Other languages
French (fr)
Other versions
WO2001025399A2 (en
Inventor
David G Bermudes
Ivan Cheung-Lam King
Ronald G Blasberg
Juri G Tjuvajev
Original Assignee
Vion Pharmaceuticals Inc
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vion Pharmaceuticals Inc, Sloan Kettering Inst Cancer filed Critical Vion Pharmaceuticals Inc
Priority to AU79936/00A priority Critical patent/AU7993600A/en
Priority to CA002386806A priority patent/CA2386806A1/en
Priority to EP00970577A priority patent/EP1414499A2/en
Publication of WO2001025399A2 publication Critical patent/WO2001025399A2/en
Publication of WO2001025399A3 publication Critical patent/WO2001025399A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0045—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0045—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo
    • A61K49/0047—Green fluorescent protein [GFP]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0097—Cells, viruses, ghosts, red blood cells, viral vectors, used for imaging or diagnosis in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

The present invention provides non-invasive compositions and methods to detect solid tumors using tumor-targeted bacteria. specifically, the present invention provides compositions and methods for detecting solid tumors in vivo by delivery of a marker gene to a solid tumor via a population of tumor-targeted bacteria, methods for detecting solid tumors by detecting a compound incorporated into the bacteria, methods for detecting solid tumors by detecting an infection caused by the bacteria at the tumor site(s), methods for detecting solid tumors by detecting an antigen present on the surface of the bacterial vectors. When detecting a tumor entails detecting a marker gene product expressed by the tumor-targeted bacteria, the marker gene product can be detected directly in the tumor, by the use of a labeled moiety that interacts with the marker gene product, or by the use of the labeled marker substrate. Thus, if a marker gene product is directly detectable, it can be detected directly. When a marker gene product is not directly detectable, a labeled moiety that interacts with the marker gene product is detected, or a labeled marker substrate is used and a labeled marker metabolite is detected. A tumor can thus be localized or detected by scanning a subject to detect the marker gene product, a labeled complex comprising the marker gene product and its interacting moiety, or a labeled marker metabolite, respectively, thereby imaging the tumor. Specifically, the attenuated tumor-targeted bacteria of the invention are facultative aerobes or facultative anaerobes which are modified to encode the marker gene. Still further, this invention provides compositions and methods of simultaneously imaging and treating a tumor in a subject using one or a plurality of populations tumor-targeted organisms. The invention provides non-invasive, clinically applicable methods for imaging tumors which can be implemented using existing imaging techniques to monitor and evaluate in vivo cancer treatments in human subjects. Kits are also provided.
PCT/US2000/027397 1999-10-04 2000-10-04 Non-invasive tumor imaging by tumor-targeted bacteria WO2001025399A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU79936/00A AU7993600A (en) 1999-10-04 2000-10-04 Non-invasive tumor imaging by tumor-targeted bacteria
CA002386806A CA2386806A1 (en) 1999-10-04 2000-10-04 Non-invasive tumor imaging by tumor-targeted bacteria
EP00970577A EP1414499A2 (en) 1999-10-04 2000-10-04 Non-invasive tumor imaging by tumor-targeted bacteria

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15762099P 1999-10-04 1999-10-04
US60/157,620 1999-10-04

Publications (2)

Publication Number Publication Date
WO2001025399A2 WO2001025399A2 (en) 2001-04-12
WO2001025399A3 true WO2001025399A3 (en) 2001-08-23

Family

ID=22564528

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/027397 WO2001025399A2 (en) 1999-10-04 2000-10-04 Non-invasive tumor imaging by tumor-targeted bacteria

Country Status (4)

Country Link
EP (1) EP1414499A2 (en)
AU (1) AU7993600A (en)
CA (1) CA2386806A1 (en)
WO (1) WO2001025399A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492534B2 (en) 2003-06-18 2016-11-15 Genelux Corporation Microorganisms for therapy

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005520781A (en) * 2001-07-09 2005-07-14 アンチキャンサー インコーポレーテッド Imaging infection using fluorescent proteins as markers
EP1281767A3 (en) * 2001-07-31 2003-05-28 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of tumors
EP1281772A1 (en) * 2001-07-31 2003-02-05 Aladar A. Szalay Light-emitting microorganisms and cells for tumour diagnosis/therapy
EP1914316B1 (en) * 2001-08-01 2009-12-16 Genelux Corporation LIVP strain of vaccinia virus for diagnosis and therapy of tumours
CN1304559C (en) * 2001-10-09 2007-03-14 杭州康科生物技术有限公司 Oncolytic microorganism expressing heat shock protein and its application
CA2470411C (en) * 2001-12-31 2015-07-07 Anticancer, Inc. System for monitoring bacterial tumor treatment
EP1369491A1 (en) * 2002-06-05 2003-12-10 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
JP4634710B2 (en) * 2002-07-31 2011-02-16 ゲネルクス コーポレーション Microorganisms and cells for tumor diagnosis and treatment
EP1594560A4 (en) * 2003-01-09 2007-06-06 Univ Pennsylvania Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector
CN101010002B (en) * 2004-06-29 2012-10-10 抗癌公司 Cancer selective auxotrophs
NZ569818A (en) 2005-12-16 2012-07-27 Catherine M Shachaf Diagnostic system for the detection and diagnosis of skin cancer
US8357486B2 (en) 2008-01-11 2013-01-22 Genelux Corporation Methods and compositions for detection of bacteria and treatment of diseases and disorders
WO2012112317A1 (en) * 2011-02-15 2012-08-23 Albert Einstein College Of Medicine Of Yeshiva University Radiobacteria for therapy of cancer
US11268958B2 (en) * 2012-09-14 2022-03-08 The Johns Hopkins University Bacteria-specific labeled substrtates as imaging biomarkers to diagnose, locate, and monitor infections
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
JP7097438B2 (en) 2017-07-11 2022-07-07 アクティム・セラピューティクス・インコーポレイテッド Genetically engineered immunostimulatory bacterial strains and their use
BR112021000315A2 (en) 2018-07-11 2021-08-03 Actym Therapeutics, Inc. Genetically modified immunostimulant bacterial strains and their uses
EP3844276A2 (en) 2018-08-28 2021-07-07 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
KR102110993B1 (en) * 2018-12-20 2020-05-14 한국생명공학연구원 Composition for diagnosing, preventing or treating cancer comprising Klebsiella aerogenes as active ingredient
CA3131017A1 (en) 2019-02-27 2020-09-03 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
CA3161450A1 (en) 2019-11-12 2021-05-20 Actym Therapeutics, Inc. Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products
AU2021324883A1 (en) 2020-08-12 2023-03-23 Actym Therapeutics, Inc. Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms
CA3235418A1 (en) 2021-11-09 2023-05-19 Actym Therapeutics, Inc. Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4841025A (en) * 1983-07-08 1989-06-20 National Research Development Corporation Antibody preparations
WO1996040238A1 (en) * 1995-06-07 1996-12-19 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
WO1997018837A1 (en) * 1995-11-22 1997-05-29 University Of Maryland At Baltimore Novel non-pyrogenic bacterial strains and use of the same
US5681745A (en) * 1995-05-01 1997-10-28 Trustees Of Boston University Biotin-binding containment systems
US5703056A (en) * 1995-03-15 1997-12-30 Sloan-Kettering Institute For Cancer Research Non-invasive imaging of gene transfer
US5824538A (en) * 1995-09-06 1998-10-20 The United States Of America As Represented By The Secretary Of The Army Shigella vector for delivering DNA to a mammalian cell
WO1999013053A1 (en) * 1997-09-10 1999-03-18 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839293A (en) * 1986-02-24 1989-06-13 The Trustees Of Columbia University In The City Of New York DNA encoding streptavidin, streptavidin produced therefrom, fused polypeptides which include amino acid sequences present in streptavidin and uses thereof
US4863713A (en) * 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4841025A (en) * 1983-07-08 1989-06-20 National Research Development Corporation Antibody preparations
US5703056A (en) * 1995-03-15 1997-12-30 Sloan-Kettering Institute For Cancer Research Non-invasive imaging of gene transfer
US5681745A (en) * 1995-05-01 1997-10-28 Trustees Of Boston University Biotin-binding containment systems
WO1996040238A1 (en) * 1995-06-07 1996-12-19 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
US5824538A (en) * 1995-09-06 1998-10-20 The United States Of America As Represented By The Secretary Of The Army Shigella vector for delivering DNA to a mammalian cell
WO1997018837A1 (en) * 1995-11-22 1997-05-29 University Of Maryland At Baltimore Novel non-pyrogenic bacterial strains and use of the same
WO1999013053A1 (en) * 1997-09-10 1999-03-18 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GALAN J.E. ET AL.: "Cloning and characterzation of the asd gene of salmonella typhimurium: use in stable maintenance of recombinant plasmids in salmonella vaccine strains", GENE, vol. 94, 1990, pages 29 - 35, XP002938373 *
HEIM R.: "Engineering green fluorescent protein for improved brightness, longer wavelengths and fluorescence resonance energy transfer", CURRENT BIOLOGY, vol. 6, no. 2, 1996, pages 178 - 182, XP002938374 *
See also references of EP1414499A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492534B2 (en) 2003-06-18 2016-11-15 Genelux Corporation Microorganisms for therapy

Also Published As

Publication number Publication date
AU7993600A (en) 2001-05-10
EP1414499A4 (en) 2004-05-06
CA2386806A1 (en) 2001-04-12
WO2001025399A2 (en) 2001-04-12
EP1414499A2 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
WO2001025399A3 (en) Non-invasive tumor imaging by tumor-targeted bacteria
Moriyama et al. Expression of c-erbB-2 gene product in urinary bladder cancer
CA2456055A1 (en) Microoroganisms and cells for diagnosis and therapy of tumors
WO2002032292A3 (en) Methods for development and use of diagnostic and therapeutic agents
BR9917218A (en) Monoclonal antibodies, antigens, and diagnosis and therapy of malignancies
Wimmer et al. Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy
IL155611A0 (en) Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc)
EP3119427B1 (en) Methods and materials for treating cancer
EP1734134A3 (en) A novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer
WO2006086343A2 (en) Chemical exchange saturation transfer based mri using reporter genes and mri methods related thereto
Ghislanzoni et al. Primary cutaneous follicular center cell lymphoma of the nose with maxillary sinus involvement in a pediatric patient
CN105648076B (en) The diagnosis and treatment target of NUDT11 gene and its expression product as fibroid
Green et al. Melanocytic naevi and melanoma in survivors of childhood cancer
Yen et al. Detection of Mycobacterium tuberculosis in erythema induratum of Bazin using polymerase chain reaction
AU2002306568A1 (en) Forms of prostate specific antigens and methods for their detection
Docimo et al. Detection of adenocarcinoma by urinary microsatellite analysis after augmentation cystoplasty
Zalaudek et al. Glomerular vessels in Bowen's disease
Ruchala et al. Immunoexpression of TTF-1 and Ki-67 in a coexistent anaplastic and follicular thyroid cancer with rare long-life surviving.
CN108707665B (en) Marker for diagnosing nasopharyngeal carcinoma
MacKie Strategies to reduce mortality from cutaneous malignant melanoma
Denschlag et al. Low-grade myxofibrosarcoma of the vulva in a 15-year-old adolescent: a case report
Arai et al. Efficacy of photodynamic diagnosis‐assisted transurethral resection of bladder tumor for T1 bladder cancer: Novel second transurethral resection initiatives utilizing photodynamic diagnosis.
CN105861740B (en) Purposes of the ABLIM3 gene as cancer of the esophagus diagnosis and treatment marker
Sousa-Coelho Targeting TRIB2 expression with oral antidiabetic drugs to overcome tumour malignancy and drug-resistance
CN105950746B (en) The diagnosis and treatment target that RASL12 gene is shifted as lung squamous cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2386806

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000970577

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000970577

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000970577

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP